Company Filing History:
1 out of 832,880 Years Active: 2004
Title: Ian D Krantz: Innovator in Alagille Syndrome Diagnosis
Introduction
Ian D Krantz is a notable inventor based in Philadelphia, PA (US). He has made significant contributions to the field of medical diagnostics, particularly in relation to Alagille Syndrome. His innovative work has led to the development of methods that enhance the understanding and diagnosis of this genetic condition.
Latest Patents
Krantz holds a patent for "Methods of diagnosing Alagille syndrome." This invention provides an isolated polypeptide that exhibits substantially the same amino acid sequence as JAGGED, or an active fragment thereof. Importantly, the polypeptide does not have the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6. Additionally, the invention includes an isolated nucleic acid molecule containing a nucleotide sequence encoding substantially the same amino acid sequence as JAGGED, with similar exclusions. The patent also outlines a method for inhibiting the differentiation of hematopoietic progenitor cells by using an isolated JAGGED polypeptide. Furthermore, it provides a method for diagnosing Alagille Syndrome by detecting disease-associated mutations linked to a JAGGED locus.
Career Highlights
Throughout his career, Ian D Krantz has focused on advancing medical research and diagnostics. His work has been instrumental in providing new insights into genetic disorders, particularly those affecting the liver and heart. His dedication to improving patient outcomes through innovative solutions is commendable.
Collaborations
Krantz has collaborated with esteemed colleagues in the field, including Linheng Li and Leroy E Hood. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in medical research.
Conclusion
Ian D Krantz is a pioneering inventor whose work in diagnosing Alagille Syndrome has the potential to significantly impact the field of genetics and patient care. His contributions reflect a commitment to innovation and improving health outcomes for individuals affected by this condition.